TY - CHAP M1 - Book, Section TI - Daptomycin A1 - Gruenberg, Katherine A1 - Guglielmo, B. Joseph A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. Y1 - 2023 N1 - T2 - Current Medical Diagnosis & Treatment 2023 AB - Daptomycin is a bactericidal lipopeptide with a spectrum of activity similar to that of linezolid or quinupristin-dalfopristin. This spectrum includes methicillin-resistant staphylococci and VRE; however, MICs are much lower for the former than the latter. Daptomycin has poor oral bioavailability and thus is only available as a parenteral product. Its long pharmacologic half-life allows for once-daily dosing (approved at 4 mg/kg every 24 hours in skin and soft tissue infection and 6 mg/kg, every 24 hours in the treatment of bacteremia and right-sided endocarditis); dosage adjustment is necessary in the presence of kidney disease. IDSA recommends 8–10 mg/kg daily to treat serious infection; doses up to 12 mg/kg are recommended by some experts for treatment of vancomycin-resistant Enterococcus. The primary adverse event associated with daptomycin is a reversible, dose-dependent myopathy observed with 7 days or more of therapy. Considering this complication, monitoring of serum creatine kinase levels is recommended, particularly in those patients receiving long-term therapy. Daptomycin cannot be used in the treatment of primary respiratory tract infection because pulmonary surfactant binds daptomycin, resulting in subtherapeutic free drug concentrations in pulmonary secretions. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193122187 ER -